A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis

Journal of Dermatological Treatment

Volumn 19, Issue 3, 2008, Pages 146-155

  Krueger, Gerald G ^a   Gottlieb, Alice B ^b   Sterry, Wolfram ^c   Korman, Neil ^d   Van De Kerkhof, Peter ^e  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alefacept; Chronic plaque psoriasis; Combination therapy; Open label clinical trial

Indexed keywords

ALEFACEPT; CORTICOSTEROID; CYCLOSPORIN; DITHRANOL; METHOTREXATE; PREDNISONE; PSORALEN; RETINOID; TAR; VITAMIN D DERIVATIVE;

ADULT; APPENDICITIS; ARTHRALGIA; ARTICLE; BACKACHE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHRONIC PLAQUE PSORIASIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INFLUENZA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NECROTIZING FASCIITIS; NEOPLASM; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PELVIS ABSCESS; PERIANAL ABSCESS; PNEUMONIA; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RHINOPHARYNGITIS; SCORING SYSTEM; SEPSIS; SIDE EFFECT; SKIN INFECTION; TOOTH INFECTION; TREATMENT OUTCOME; TUBERCULOSIS; ULTRAVIOLET B RADIATION; UPPER RESPIRATORY TRACT INFECTION; VIRUS REACTIVATION;

ADULT; CD4 LYMPHOCYTE COUNT; CYCLOSPORINE; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; LYMPHOPENIA; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASMS; PSORIASIS; RECOMBINANT FUSION PROTEINS; RETINOIDS; RETREATMENT; TREATMENT OUTCOME; ULTRAVIOLET THERAPY;

EID: 45849086165     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630701846103     Document Type: Article

References (20)

1. Christophers E. Psoriasis - Epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26:314-20.
2. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136-9.
3. Salonen S-H, for the EUROPSO Patient Survey Study Group, The EUROPSO psoriasis patient study: Treatment history and satisfaction reported by 17,990 members of European psoriasis patient associations. Accessed on July 31, 2007. URL: http://www.europso.org, 2002.
4. Van de Kerkhof P, Salonen S-H, for the EUROPSO Patient Survey Study Group, Large-scale European survey of quality of life in patients with psoriasis: Second phase results on quality of life and treatment reported by 7,525 members of European psoriasis patient associations. Accessed on July 31, 2007. URL: http://www.europso.org, 2003.
5. Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004;50:416-30.
6. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/ function analysis in vitro and in human CD2 transgenic mice. J Immunol. 1994;152:2753-67.
7. Meier W, Gill A, Rogge M, Dabora R, Majeau GR, Oleson FB, et al. Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: Cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Ther Immunol. 1995;2:159-71.
8. Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa MD, et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med. 1993;178:211-22.
9. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001;345:248-55.
10. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002;47:821-33.
11. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719-27.
12. Lowe NJ, Gonzalez J, Bagel J, Caro I, Ellis CN, Menter A. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol. 2003;42:224-30.
13. Gordon KB, Langley RG. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol. 2003;2:624-8.
14. Menter A, Cather JC, Baker D, Farber HF, Lebwohl M, Darif M. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol. 2006;54:61-3.
15. Van Duijnhoven MW, de Jong EM, Gerritsen WJ, Pasch MC, van de Kerkhof PC. Alefacept modifies long-term disease severity and improves the response to other treatments. Eur J Dermatol. 2005;15:366-73.
16. Ortonne JP, Khemis A, Koo JY, Choi J. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2005;19:556-63.
17. Scheinfeld N. Therapy-resistant psoriasis treated with alefacept and subsequent narrow band ultraviolet B phototherapy with total clearing of psoriasis. Dermatol Online J. 2005;11:7.
18. Goffe B, Papp K, Gratton D, Krueger GG, Darif M, Lee S, et al. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther. 2005;27:1912-21.
19. Ticho B, Bozic C, Cather JC. A simple algorithm for reduced lymphocyte monitoring with alefacept therapy. J Am Acad Dermatol. 2005;52:P174.
20. Al-Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol. 2000;42:796-802.